Research progress of sintilimab in the treatment of cancer (Review)
- Authors:
- Yuan-Yuan Wu
- Hua Shao
-
Affiliations: Department of Pharmacy, Zhongda Hospital of Southeast University, Nanjing, Jiangsu 210009, P.R. China - Published online on: March 21, 2025 https://doi.org/10.3892/ol.2025.14986
- Article Number: 240
-
Copyright: © Wu et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
 |
|
de Visser KE and Joyce JA: The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth. Cancer Cell. 41:374–403. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Dhanasekaran R, Deutzmann A, Mahauad-Fernandez WD, Hansen AS, Gouw AM and Felsher DW: The MYC oncogene-the grand orchestrator of cancer growth and immune evasion. Nat Rev Clin Oncol. 19:23–36. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Hill W, Weeden CE and Swanton C: Tumor promoters and opportunities for molecular cancer prevention. Cancer Discov. 14:1154–1160. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Gilbertson RJ: Mapping cancer origins. Cell. 145:25–29. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Curtius K, Wright NA and Graham TA: An evolutionary perspective on field cancerization. Nat Rev Cancer. 18:19–32. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mullard A: Addressing cancer's grand challenges. Nat Rev Drug Discov. 19:825–826. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Boshuizen J and Peeper DS: Rational cancer treatment combinations: An urgent clinical need. Mol Cell. 78:1002–1018. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang Y and Zhang Z: The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol. 17:807–821. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Szeto GL and Finley SD: Integrative approaches to cancer immunotherapy. Trends Cancer. 5:400–410. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Hoy SM: Sintilimab: First global approval. Drugs. 79:341–346. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Chen S, Li T, Yang W, Wang T, Qin Y, Du Z, Li Y, Cui P, Hu Y and Liu Z: Comparative efficacy of six programmed cell death protein-1 inhibitors as first-line treatment for advanced non-small cell lung cancer: A multicenter retrospective cohort study. Front Pharmacol. 15:13908722024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Qian Y, Li J, Cui C, Chen L, Qu S and Lu S: Indirect comparison of sintilimab and other PD-L1 inhibitors for first-line treatment of non-squamous non-small-cell lung cancer. Future Oncol. 18:1896–1905. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Kaplon H, Chenoweth A, Crescioli S and Reichert JM: Antibodies to watch in 2022. MAbs. 14:20142962022. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Lin W, Tan F, Li N, Xue Q, Gao S, Gao Y and He J: Sintilimab for the treatment of non-small cell lung cancer. Biomark Res. 10:232022. View Article : Google Scholar : PubMed/NCBI | |
|
Lou B, Wei H, Yang F, Wang S, Yang B, Zheng Y, Zhu J and Yan S: preclinical characterization of GLS-010 (Zimberelimab), a novel fully human anti-PD-1 therapeutic monoclonal antibody for cancer. Front Oncol. 11:7369552021. View Article : Google Scholar : PubMed/NCBI | |
|
Mao C, Xiong A, Qian J, Wang W, Liu Y, Zhang T, Wu Z, Ni H, Lu J, Long S, et al: Dual inhibition of LAG-3 and PD-1 with IBI110 and sintilimab in advanced solid tumors: The first-in-human phase Ia/Ib study. J Hematol Oncol. 17:1322024. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Mai W, Jiang W and Geng Q: Sintilimab: A promising anti-tumor PD-1 antibody. Front Oncol. 10:5945582020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X and Yi Y: Recent updates on Sintilimab in solid tumor immunotherapy. Biomark Res. 8:692020. View Article : Google Scholar : PubMed/NCBI | |
|
Gao S, Li N, Gao S, Xue Q, Ying J, Wang S, Tao X, Zhao J, Mao Y, Wang B, et al: Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 15:816–826. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ye Z, Yang W, Xuan B, Li X, He J, Si H and Ma W: Efficacy and safety evaluation of sintilimab for cancer treatment: A systematic review and meta-analysis of randomized controlled trials. Front Pharmacol. 13:8951872022. View Article : Google Scholar : PubMed/NCBI | |
|
Hu J, Li Y, Chen X, Luo C and Zuo X: Pulmonary fibrosis and cytokine release syndrome after hyperactivation with sintilimab. J Clin Pharm Ther. 45:1474–1477. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A and Suárez-Almazor ME: Immune-related adverse events of checkpoint inhibitors. Nat Rev Dis Primers. 6:382020. View Article : Google Scholar : PubMed/NCBI | |
|
Huang Y, Zhu L, Ma X, Hong Y, Su X, Lai W and Gong Z: A case of sintilimab-induced SJS/TEN:Dermatologic adverse reactions associated with programmed cell death protein-1 inhibitors. Dermatol Ther. 35:e156632022. View Article : Google Scholar : PubMed/NCBI | |
|
Tang M, Dang P, Liu T, Yang K, Wang Y, Tse G, Liu H, Liu Y, Chan JSK, Liu C and Li G: Risk factors and outcomes of pericardial effusion in cancer patients receiving PD-1 inhibitors. Int J Cardiol. 407:1320292024. View Article : Google Scholar : PubMed/NCBI | |
|
Miao D, Zhao J, Han Y, Zhou J, Li X, Zhang T, Li W and Xia Y: Management of locally advanced non-small cell lung cancer: State of the art and future directions. Cancer Commun (Lond). 44:23–46. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Mountzios G, Remon J, Hendriks LEL, García-Campelo R, Rolfo C, Van Schil P, Forde PM, Besse B, Subbiah V, Reck M, et al: Immune-checkpoint inhibition for resectable non-small-cell lung cancer-opportunities and challenges. Nat Rev Clin Oncol. 20:664–677. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang L, Wang Z, Fang J, Yu Q, Han B, Cang S, Chen G, Mei X, Yang Z, Stefaniak V, et al: Final overall survival data of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC in the phase 3 ORIENT-11 study. Lung Cancer. 171:56–60. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Yang Y, Zhou H and Zhang L: Response to letter to the editor: Efficacy and safety of sintilimab plus pemetrexed and platinum as first-line treatment for locally advanced or metastatic nonsquamous NSCLC: A randomized, double-blind, phase 3 study (ORIENT-11). J Thorac Oncol. 15:e191–e192. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Liu SYM, Huang J, Deng JY, Xu CR, Yan HH, Yang MY, Li YS, Ke EE, Zheng MY, Wang Z, et al: PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Sci Bull (Beijing). 69:535–543. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Dehghani T, Shahrjerdi A, Kahrizi MS, Soleimani E, Ravandeh S, Merza MS, Rahnama N, Ebrahimzadeh F and Bakhshesh M: Targeting programmed cell death protein 1 (PD-1) for treatment of non-small-cell lung carcinoma (NSCLC); the recent advances. Pathol Res Pract. 246:1544702023. View Article : Google Scholar : PubMed/NCBI | |
|
Cuesta ÁM, Palao N, Bragado P, Gutierrez-Uzquiza A, Herrera B, Sánchez A and Porras A: New and old key players in liver cancer. Int J Mol Sci. 24:171522023. View Article : Google Scholar : PubMed/NCBI | |
|
Brown ZJ, Tsilimigras DI, Ruff SM, Mohseni A, Kamel IR, Cloyd JM and Pawlik TM: Management of hepatocellular carcinoma: A review. JAMA Surg. 158:410–420. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Llovet JM, Pinyol R, Yarchoan M, Singal AG, Marron TU, Schwartz M, Pikarsky E, Kudo M and Finn RS: Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma. Nat Rev Clin Oncol. 21:294–311. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Ren Z, Xu J, Bai Y, Xu A, Cang S, Du C, Li Q, Lu Y, Chen Y, Guo Y, et al: Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2–3 study. Lancet Oncol. 22:977–990. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Sidaway P: Adjuvant sintilimab effective in high-risk HCC. Nat Rev Clin Oncol. 21:1682024. View Article : Google Scholar : PubMed/NCBI | |
|
Karimi P, Islami F, Anandasabapathy S, Freedman ND and Kamangar F: Gastric cancer: Descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev. 23:700–713. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Smyth EC, Nilsson M, Grabsch HI, van Grieken NC and Lordick F: Gastric cancer. Lancet. 396:635–648. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Shitara K: Chemotherapy for advanced gastric cancer: Future perspective in Japan. Gastric Cancer. 20 (Suppl 1):S102–S110. 2017. View Article : Google Scholar | |
|
Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, Chen JS, Muro K, Kang WK, et al: Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 390:2461–2471. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Taieb J, Moehler M, Boku N, Ajani JA, Ruiz EY, Ryu MH, Guenther S, Chand V and Bang YJ: Evolution of checkpoint inhibitors for the treatment of metastatic gastric cancers: Current status and future perspectives. Cancer Treat Rev. 66:104–113. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Mei Y, Shi M and Zhu Z, Yuan H, Yan C, Li C, Feng T, Yan M, Zhang J and Zhu Z: Addition of sintilimab to nanoparticle albumin-bound paclitaxel and S-1 as adjuvant therapy in stage IIIC gastric cancer. Future Oncol. 18:139–148. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, Wyrwicz L, Yamaguchi K, Skoczylas T, Bragagnoli AC, et al: First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): A randomised, open-label, phase 3 trial. Lancet. 398:27–40. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Xu J, Jiang H, Pan Y, Gu K, Cang S, Han L, Shu Y, Li J, Zhao J, Pan H, et al: Sintilimab Plus chemotherapy for unresectable gastric or gastroesophageal junction cancer: The ORIENT-16 randomized clinical trial. JAMA. 330:2064–2074. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Mwachiro M and White R: Management of esophageal cancer treatment in resource-limited settings. Thorac Surg Clin. 32:397–404. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Huang FL and Yu SJ: Esophageal cancer: Risk factors, genetic association, and treatment. Asian J Surg. 41:210–215. 2018. View Article : Google Scholar : PubMed/NCBI | |
|
Li Q, Liu T and Ding Z: Neoadjuvant immunotherapy for resectable esophageal cancer: A review. Front Immunol. 13:10518412022. View Article : Google Scholar : PubMed/NCBI | |
|
Yokota T, Ando N, Igaki H, Shinoda M, Kato K, Mizusawa J, Katayama H, Nakamura K, Fukuda H and Kitagawa Y: Prognostic factors in patients receiving neoadjuvant 5-fluorouracil plus cisplatin for advanced esophageal cancer (JCOG9907). Oncology. 89:143–151. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Lu Z, Wang J, Shu Y, Liu L, Kong L, Yang L, Wang B, Sun G, Ji Y, Cao G, et al: Sintilimab versus placebo in combination with chemotherapy as first line treatment for locally advanced or metastatic oesophageal squamous cell carcinoma (ORIENT-15): Multicentre, randomised, double blind, phase 3 trial. BMJ. 377:e0687142022. View Article : Google Scholar : PubMed/NCBI | |
|
Benson AB, D'Angelica MI, Abrams T, Abbott DE, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Binder D, et al: NCCN guidelines® insights: Biliary tract cancers, version 2.2023. J Natl Compr Canc Netw. 21:694–704. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Kalyan A, Khosla H and Kim RD: Immunotherapy in biliary tract cancers: Where are we? Curr Oncol Rep. 24:1821–1828. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Feng L, Wang Y, Xu H and Yi F: Comparison of different first-line systemic therapies in advanced biliary tract cancer based on updated random controlled trials: A systematic review and network meta-analysis. Biomed Res Int. 2022:17206962022. View Article : Google Scholar : PubMed/NCBI | |
|
Zeng TM, Yang G, Lou C, Wei W, Tao CJ, Chen XY, Han Q, Cheng Z, Shang PP, Dong YL, et al: Clinical and biomarker analyses of sintilimab plus gemcitabine and cisplatin as first-line treatment for patients with advanced biliary tract cancer. Nat Commun. 14:13402023. View Article : Google Scholar : PubMed/NCBI | |
|
Jin S, Zhao R, Zhou C, Zhong Q, Shi J, Su C, Li Q, Su X, Chi H, Lu X, et al: Feasibility and tolerability of sintilimab plus anlotinib as the second-line therapy for patients with advanced biliary tract cancers: An open-label, single-arm, phase II clinical trial. Int J Cancer. 152:1648–1658. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Vincent A, Herman J, Schulick R, Hruban RH and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Klein AP: Pancreatic cancer epidemiology: Understanding the role of lifestyle and inherited risk factors. Nat Rev Gastroenterol Hepatol. 18:493–502. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Koikawa K, Kibe S, Suizu F, Sekino N, Kim N, Manz TD, Pinch BJ, Akshinthala D, Verma A, Gaglia G, et al: Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Cell. 184:4753–4771.e27. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
McGrail DJ, Pilié PG, Rashid NU, Voorwerk L, Slagter M, Kok M, Jonasch E, Khasraw M, Heimberger AB and Lim B: High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types. Ann Oncol. 32:661–672. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Fu Q, Chen Y, Huang D, Guo C, Zhang X, Xiao W, Xue X, Zhang Q, Li X, Gao S, et al: Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: The randomized phase II CISPD3 trial. Ann Surg Oncol. 30:5071–5080. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Zhou SQ, Wan P, Zhang S, Ren Y, Li HT and Ke QH: Programmed cell death 1 inhibitor sintilimab plus concurrent chemoradiotherapy for locally advanced pancreatic adenocarcinoma. World J Clin Oncol. 15:859–866. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Qiu X, Lu C, Sha H, Zhu Y, Kong W, Tong F, Wang Q, Meng F, Liu B and Du J: Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: A single-arm, phase II clinical trial. Front Immunol. 15:12108592024. View Article : Google Scholar : PubMed/NCBI | |
|
Dekker E, Tanis PJ, Vleugels JLA, Kasi PM and Wallace MB: Colorectal cancer. Lancet. 394:1467–1480. 2019. View Article : Google Scholar : PubMed/NCBI | |
|
Zhang X, Wu T, Cai X, Dong J, Xia C, Zhou Y, Ding R, Yang R, Tan J, Zhang L, et al: Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: New strategies and unveiled opportunities. Front Immunol. 13:7959722022. View Article : Google Scholar : PubMed/NCBI | |
|
Diaz LA Jr, Shiu KK, Kim TW, Jensen BV, Jensen LH, Punt C, Smith D, Garcia-Carbonero R, Benavides M, Gibbs P, et al: Pembrolizumab versus chemotherapy for microsatellite instability-high or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): Final analysis of a randomised, open-label, phase 3 study. Lancet Oncol. 23:659–670. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Xiao WW, Chen G, Gao YH, Lin JZ, Wu XJ, Luo HL, Lu ZH, Wang QX, Sun R, Cai PQ, et al: Effect of neoadjuvant chemoradiotherapy with or without PD-1 antibody sintilimab in pMMR locally advanced rectal cancer: A randomized clinical trial. Cancer Cell. 42:1570–1581. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Chen G, Jin Y, Guan WL, Zhang RX, Xiao WW, Cai PQ, Liu M, Lin JZ, Wang FL, Li C, et al: Neoadjuvant PD-1 blockade with sintilimab in mismatch-repair deficient, locally advanced rectal cancer: An open-label, single-centre phase 2 study. Lancet Gastroenterol Hepatol. 8:422–431. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Abu-Rustum NR, Yashar CM, Arend R, Barber E, Bradley K, Brooks R, Campos SM, Chino J, Chon HS, Crispens MA, et al: NCCN Guidelines® insights: Cervical cancer, version 1.2024. J Natl Compr Canc Netw. 21:1224–1233. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Gadducci A and Cosio S: Neoadjuvant chemotherapy in locally advanced cervical cancer: Review of the literature and perspectives of clinical research. Anticancer Res. 40:4819–4828. 2020. View Article : Google Scholar : PubMed/NCBI | |
|
Monk BJ, Colombo N, Tewari KS, Dubot C, Caceres MV, Hasegawa K, Shapira-Frommer R, Salman P, Yañez E, Gümüş M, et al: First-line pembrolizumab + chemotherapy versus placebo + chemotherapy for persistent, recurrent, or metastatic cervical cancer: Final overall survival results of KEYNOTE-826. J Clin Oncol. 41:5505–5511. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Wang Y, Zhao J, Liang H, Liu J, Huang S, Zou G, Huang X and Lan C: Efficacy and safety of sintilimab plus albumin-bound-paclitaxel in recurrent or metastatic cervical cancer: A multicenter, open-label, single-arm, phase II trial. EClinicalMedicine. 65:1022742023. View Article : Google Scholar : PubMed/NCBI | |
|
Xu Q, Wang J, Sun Y, Lin Y, Liu J, Zhuo Y, Huang Z, Huang S, Chen Y, Chen L, et al: Efficacy and safety of sintilimab plus anlotinib for PD-L1-positive recurrent or metastatic cervical cancer: A multicenter, single-arm, prospective phase II trial. J Clin Oncol. 40:1795–1805. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Cuthbertson DJ, Shankland R and Srirajaskanthan R: Diagnosis and management of neuroendocrine tumours. Clin Med (Lond). 23:119–124. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Jia R, Li Y, Xu N, Jiang HP, Zhao CH, Liu RR, Shi Y, Zhang YY, Wang SY, Zhou H and Xu JM: Sintilimab in patients with previously treated metastatic neuroendocrine neoplasms. Oncologist. 27:e625–e632. 2022. View Article : Google Scholar : PubMed/NCBI | |
|
Liu X, Zhang Y, Yang KY, Zhang N, Jin F, Zou GR, Zhu XD, Xie FY, Liang XY, Li WF, et al: Induction-concurrent chemoradiotherapy with or without sintilimab in patients with locoregionally advanced nasopharyngeal carcinoma in China (CONTINUUM): A multicentre, open-label, parallel-group, randomised, controlled, phase 3 trial. Lancet. 403:2720–2731. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
Tian Z, Dong S, Yang Y, Gao S, Yang Y, Yang J, Zhang P, Wang X and Yao W: Nanoparticle albumin-bound paclitaxel and PD-1 inhibitor (sintilimab) combination therapy for soft tissue sarcoma: A retrospective study. BMC Cancer. 22:562022. View Article : Google Scholar : PubMed/NCBI | |
|
Lu X, Gu W, Shi G and Ye D: Pazopanib together with 6–8 cycles of sintilimab followed by single use of pazopanib in the second-line treatment of advanced renal cell carcinoma. Transl Androl Urol. 10:2078–2083. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Fang Q, Du W, Zhang X, Dai L and Qiao Y: Induction chemotherapy combined with immunotherapy in locally advanced head and neck squamous cell carcinoma. BMC Cancer. 21:6222021. View Article : Google Scholar : PubMed/NCBI | |
|
Li R, Liu X, Song C, Zhang W, Liu J, Jiao X, Yu Y, Zeng S, Chi J, Zhao Y, et al: Sintilimab combined with bevacizumab in relapsed/persistent ovarian clear cell carcinoma (INOVA): An investigator-initiated, multicentre clinical trial-a study protocol of clinical trial. BMJ Open. 12:e0581322022. View Article : Google Scholar : PubMed/NCBI | |
|
Wei W, Ban X, Yang F, Li J, Cheng X, Zhang R, Huang X, Huang Y, Li Q, Qiu Y, et al: Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer. J Immunother Cancer. 10:e0043382022. View Article : Google Scholar : PubMed/NCBI | |
|
Yao G, Huang J, Zhang Q, Hu D, Yuan F and Han G: Excellent response of refractory triple-negative breast cancer to sintilimab plus chemotherapy: A case report. Immunotherapy. 15:221–228. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, Lu S, Kemberling H, Wilt C, Luber BS, et al: Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 357:409–413. 2017. View Article : Google Scholar : PubMed/NCBI | |
|
Molife C, Brnabic A, Stefaniak VJ, Belger MA, Gruver K, Chen JV, Souri S and Blumenschein GR Jr: Sintilimab plus chemotherapy for first-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer: Network meta-analysis. Immunotherapy. 15:293–309. 2023. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Chen Y, Xiao D, Jiang S and Yang Y: Cost-Effectiveness analysis of sintilimab plus chemotherapy in advanced non-squamous non-small cell lung cancer: A societal perspective. Adv Ther. 41:1436–1449. 2024. View Article : Google Scholar : PubMed/NCBI | |
|
He J, Huang Z, Han L, Gong Y and Xie C: Mechanisms and management of 3rd-generation EGFR-TKI resistance in advanced non-small cell lung cancer (Review). Int J Oncol. 59:902021. View Article : Google Scholar : PubMed/NCBI | |
|
Sangro B, Sarobe P, Hervás-Stubbs S and Melero I: Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 18:525–543. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Cheng J, Li Y, Wang X, Dong Z, Chen Y, Zhang R, Huang J, Jin X, Yao J, Ge A, et al: Response stratification in the first-line combined immunotherapy of hepatocellular carcinoma at genomic, transcriptional and immune repertoire levels. J Hepatocell Carcinoma. 8:1281–1295. 2021. View Article : Google Scholar : PubMed/NCBI | |
|
Wang S, Yuan P, Mao B, Li N, Ying J, Tao X, Tang W, Zhang L, Geng X, Zhang F, et al: Genomic features and tumor immune microenvironment alteration in NSCLC treated with neoadjuvant PD-1 blockade. NPJ Precis Oncol. 6:22022. View Article : Google Scholar : PubMed/NCBI |
